Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Acta Dermato-Venereologica · 2023
DOI: 10.2340/actadv.v103.5243 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2023. Verfasst von Celeste M Boesjes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlan…. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index ≤ 7 and Numerical Rating Scale – pruritus ≤ 4 were 73.0% (53.7–86.3) and 69.4% (48.7–84.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and/or baricitinib and in patients who were naïve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n = 10, 21.3%), herpes simplex (n = 6, 12.8%), nausea and airway infections (both n = 4, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and/or baricitinib treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands. c.m.boesjes-2@umcutrecht.nl.
- Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Dermatology, Reinier de Graaf Gasthuis, Delft, The Netherlands.
- Department of Dermatology, Radboud University Medical Center, Radboud University, The Netherlands.
Zitieren
APA
Boesjes, C. M., Van der Gang, L. F., Zuithoff, N. P. A., Bakker, D. S., Spekhorst, L. S., Haeck, I., Kamsteeg, M., De Graaf, M., & De Bruin-Weller, M. S. (2023). Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v103.5243
Vancouver
Boesjes CM, Van der Gang LF, Zuithoff NPA, Bakker DS, Spekhorst LS, Haeck I, et al. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry. Acta Dermato-Venereologica. 2023. doi:10.2340/actadv.v103.5243
BibTeX
@article{Boesjes2023,
author = {Boesjes, Celeste M and Van der Gang, Liana F and Zuithoff, Nicolaas P A and Bakker, Daphne S and Spekhorst, Lotte S and Haeck, Inge and Kamsteeg, Marijke and De Graaf, Marlies and De Bruin-Weller, Marjolein S},
title = {Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry},
journal = {Acta Dermato-Venereologica},
year = {2023},
doi = {10.2340/actadv.v103.5243}
}
EUVIMED